UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant \boxtimes

Filed by a Party other than the Registrant \Box

Check the appropriate box:

- Preliminary Proxy Statement
- □ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- □ Soliciting Material Pursuant to §240.14a-12

Silverback Therapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies:
 - (2) Aggregate number of securities to which transaction applies:
 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 - (4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

□ Fee paid previously with preliminary materials.

- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:



P.O. BOX 8016, CARY, NC 27512-9903

Silverback Therapeutics, Inc. Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to be held on June 04, 2021

For Stockholders as of record on April 06, 2021

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the Proxy Statement and the 2020 Annaul Report, and to obtain directions to attend meeting, go to: www.proxydocs.com/SBTX

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet.




For a convenient way to view proxy materials and VOTE go to www.proxydocs.com/SBTX

Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions.

If you want to receive a paper or e-mail copy of the proxy material(s), you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 25, 2021.

To order paper materials, use one of the following methods.



Silverback Therapeutics, Inc.

Meeting Type: Annual Meeting of Stockholders Date: Friday, June 04, 2021

- Time: 08:30 AM, Pacific Time
- Place: Annual Meeting to be held live via the Internet please visit
- www.proxydocs.com/SBTX for more details.

You must register to attend the meeting online and/or participate at www.proxydocs.com/SBTX

SEE REVERSE FOR FULL AGENDA

Silverback Therapeutics, Inc.

Annual Meeting of Stockholders

MANAGEMENT RECOMMENDS A VOTE:

FOR ON PROPOSALS 1 AND 2

PROPOSAL

 To elect the three nominees for Class I director named in the accompanying proxy statement to serve for three-year terms until the 2024 Annual Meeting of Stockholders.

1.01 Vickie L. Capps 1.02 Robert Hershberg, M.D., Ph.D. 1.03 Maria Koehler, M.D., Ph.D.

- To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021.
- 3. To conduct any other business properly brought before the meeting.